New treatment aims to save esophagus in cancer patients
NCT ID NCT06869226
Summary
This study is testing whether giving a combination of an immunotherapy drug (camrelizumab) and chemotherapy before surgery can shrink tumors enough to preserve the esophagus in patients with a type of esophageal cancer. The goal is to see if this approach can control the cancer effectively while allowing patients to keep their esophagus, potentially improving their quality of life after treatment. Researchers will measure how long patients live without their cancer getting worse and how many achieve complete remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.